BigNews.Biz - Apr 13,2017 - Menendez Visits Rutgers Cancer Institute of NJ to Illustrate the Impact of Trump Proposed Budget Cuts on Lifesaving Biomedical Research that Leads to New Cures, Treatments
NEW BRUNSWICK, N.J. – During a visit to the Rutgers Cancer Institute of New Jersey, U.S. Senator Bob Menendez and several of the state’s top biomedical researchers and experts, outlined the devastating impact the Trump Administration’s proposed budget cuts to the National Institutes of Health (NIH) would have on lifesaving biomedical research, and treatments of diseases and neurological disorders. New Jersey is the nation’s second largest recipient of NIH funding in the nation.
“A budget is a reflection of priorities,” said Sen. Menendez. “The cuts proposed by the Trump Administration send a message that the research being done right here by some of nation’s most brilliant minds is not a priority. It says the breakthrough discoveries that could potentially help someone like my mother in her fight against Alzheimer’s or give a terminally-ill child a shot at a healthy, happy life – is not worthy of federal investment. That’s not a message I want to send.”
Senator Menendez also tweeted this video of Dr. Steven Libutti, Director of Rutgers Cancer Center of New Jersey, explaining how devastating NIH cuts would be.
President Trump’s proposed budget would reduce NIH funding by $1.2 billion for the remainder of 2017 and impose another $5.8 billion in cuts in 2018. In 2016, New Jersey received over $240 million in grants and contracts from the NIH, which supported 5,000 jobs across the state and spurring an additional $890 million in economic activity. Rutgers University is the top recipient of NIH funds in the state, receiving awards totaling $55.8 million in 2016. In 2016, The Cancer Institute of New Jersey received awards totaling $12.2 million.
CLICK TO WATCH VIDEO
Remarks by Dr. Libutti begin here.
Remarks by Dee Sparacio, former clinical trial
participant survivor and advocate, begin here.
CLICK HERE TO DOWNLOAD HI-RES PHOTOS
“It is a transformational time in cancer research,” said Dr. Steven Libutti, Director of Rutgers Cancer Center of New Jersey. “One where collaboration amongst scientists is at the crux of our progress in cancer care and helping us to achieve greater impact that leads to improved patient outcomes. Rather than reducing NIH funding we should be increasing it in a sustained way in order not to put our progress in jeopardy.”
Dr. Gary Aston-Jones, Director of the Brain Health Institute, explained how cuts to federal funding would severely hamper their research efforts into debilitating neurological and neuropsychiatric disorders – both today and in the future.
“Not only would these cuts delay new therapies, but also would result in a loss of a generation of neuroscientists and therefore have a long-lasting negative impact on healthcare,” Dr. Aston-Jones said. “Brain disorders are some of the most devastating health problems. The enormous complexity of the brain demands that the best minds and technologies be used to understand and treat brain disorders. The resources invested